DENV-IN-16
DENV-IN-16 is a DENV2 E protein binding inhibitor with inhibitory activity against Dengue Virus. DENV-IN-16 blocks the attachment of viral particles to host cells and inhibits DENV attachment/entry at the early stage of the viral life cycle. DENV-IN-16 exhibits antiviral activity against DENV2, DENV1, DENV3, and DENV4, and shows protective efficacy in DENV2-infected AG129 mice. DENV-IN-16 can be used for research on dengue virus infection.
For research use only. We do not sell to patients.
- Formula: C36H43N5O3
- Molecular Weight:593.76
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Vero 76 | IC50 |
8.6 μM
|
Antiviral activity against Dengue virus serotype 2 in african green monkey Vero 76 cells assessed as inhibition of NS5 expression incubated for 24 hrs.
Antiviral activity against Dengue virus serotype 2 in african green monkey Vero 76 cells assessed as inhibition of NS5 expression incubated for 24 hrs.
|
42567122 |
| Vero 76 | CC50 |
184.0 μM
|
Cytotoxicity against african green monkey Vero 76 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay.
Cytotoxicity against african green monkey Vero 76 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay.
|
42567122 |
| Vero 76 | IC50 |
12.6 μM
|
Antiviral activity against Dengue virus serotype 1 in african green monkey Vero 76 cells assessed as reduction in percentage of Alexa Fluor 488-positive cells stained with pan-flavivirus anti-E monoclonal antibody 4G2 at 24 hrs post-infection by flow cytometry.
Antiviral activity against Dengue virus serotype 1 in african green monkey Vero 76 cells assessed as reduction in percentage of Alexa Fluor 488-positive cells stained with pan-flavivirus anti-E monoclonal antibody 4G2 at 24 hrs post-infection by flow cytometry.
|
42567122 |
| Vero 76 | IC50 |
6.9 μM
|
Antiviral activity against Dengue virus serotype 3 in african green monkey Vero 76 cells assessed as reduction in percentage of Alexa Fluor 488-positive cells stained with pan-flavivirus anti-E monoclonal antibody 4G2 at 24 hrs post-infection by flow cytometry.
Antiviral activity against Dengue virus serotype 3 in african green monkey Vero 76 cells assessed as reduction in percentage of Alexa Fluor 488-positive cells stained with pan-flavivirus anti-E monoclonal antibody 4G2 at 24 hrs post-infection by flow cytometry.
|
42567122 |
| Vero 76 | IC50 |
12.3 μM
|
Antiviral activity against Dengue virus serotype 4 in african green monkey Vero 76 cells assessed as reduction in percentage of Alexa Fluor 488-positive cells stained with pan-flavivirus anti-E monoclonal antibody 4G2 at 24 hrs post-infection by flow cytometry.
Antiviral activity against Dengue virus serotype 4 in african green monkey Vero 76 cells assessed as reduction in percentage of Alexa Fluor 488-positive cells stained with pan-flavivirus anti-E monoclonal antibody 4G2 at 24 hrs post-infection by flow cytometry.
|
42567122 |
In Vitro
DENV-IN-16 (compound 13e) (8-512 μM; 24 h) exhibits potent anti-DENV2 activity in Vero 76 cells with an IC50 of 8.6 μM and a selectivity index of 21.4; it also shows broad-spectrum antiviral activity against DENV1, DENV3, and DENV4 in Vero 76 cells with IC50 values of 12.6, 6.9, and 12.3 μM, respectively[1].
DENV-IN-16 exhibits antiviral activity against DENV2 in Huh-7 cells[1].
DENV-IN-16 selectively targets the early entry step of the DENV2 life cycle in Vero 76 cells[1].
DENV-IN-16 blocks DENV2 virus entry into Vero 76 cells; it blocks DENV2 infection by inhibiting the attachment of the viral glycoprotein to the surface of Vero 76 host cells[1].
DENV-IN-16 directly binds DENV2 E protein with stepwise dissociation constants of 7.2 μM and 8.1 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female AG129 mice (6-7 weeks old) were intraperitoneally challenged with a dose of DENV2 (1 × 106 focus-forming units per mouse)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; every 2 days; until day 6 post-infection
-
Result:Improved survival, with most treated animals surviving through the 14-day observation period despite one death on day 12.
Prevented weight loss and mortality.
Significantly suppressed viremia, with lower serum viral RNA copies compared to untreated infected mice.
Preserved tissue morphology in the intestine, liver, and spleen.
Chemical Information
-
Molecular Weight 593.76
-
Formula C36H43N5O3
-
SMILES
O=C1C2=C(C=CC(NC(CCN3CCCC3)=O)=C2)N(CC4=CC=C(C)C(C)=C4)C5=C1C=C(NC(CCN6CCCC6)=O)C=C5
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Immunoprecipitation
Immunoprecipitation (IP) is an experimental method that uses the principle of antibody specific binding to purify and enrich target proteins.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
DENV-IN-16 Related Classifications
HY-189423 Related Classifications
Powered by Bioz